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Objective: Peripheral arterial disease (PAD) has been associated with skeletal muscle pathology, including atrophy of the
affected muscles. In addition, oxidative metabolism is impaired, muscle function is reduced, and gait and mobility are
restricted. We hypothesized that greater severity of symptomatic PAD would be associated with lower levels of muscle
mass, strength, and endurance, and that these musculoskeletal abnormalities in turn would impair functional performance
and walking ability in patients with PAD.
Methods: We assessed 22 persons with intermittent claudication from PAD in this cross-sectional pilot study. Outcome
assessments included initial claudication distance and absolute claudication distance via treadmill protocols and outcomes
from the 6-minute walk (6MW). Secondary outcomes included one repetition maximum strength/endurance testing of
hip extensors, hip abductors, quadriceps, hamstrings, plantar ﬂexors, pectoral, and upper back muscle groups, as well as
performance-based tests of function. Univariate and stepwise multiple regression models were constructed to evaluate
relationships and are presented.
Results: Twenty-two participants (63.6% male; mean [standard deviation] age, 73.6 [8.2] years; range, 55-85 years)
were studied. Mean (standard deviation) resting ankle-brachial index (ABI) was 0.54 ([0.13]; range, 0.28-0.82), and
participants ranged from having mild claudication to rest pain. Lower resting ABI was signiﬁcantly associated with
reduced bilateral hip extensor strength (r [ 0.54; P [ .007) and reduced whole body strength (r [ 0.32; P [ .05).
In addition, lower ABI was associated with a shorter distance to ﬁrst stop during the 6MW (r [ 0.38; P [ .05) and
poorer single leg balance (r [ 0.44; P [ .03). Reduced bilateral hip extensor strength was also signiﬁcantly
associated with functional outcomes, including reduced 6MW distance to ﬁrst stop (r [ 0.74; P [ .001), reduced
6MW distance (r [ 0.75; P < .001), and reduced total short physical performance battery score (worse function; r [
0.75; P [ .003).
Conclusions: Our results suggest the existence of a causal pathway from a reduction in ABI to muscle atrophy and
weakness, to whole body disability represented by claudication outcomes and performance-based tests of functional
mobility in an older cohort with symptomatic PAD. Longitudinal outcomes from this study and future trials are required
to investigate the effects of an anabolic intervention targeting the muscles involved in mobility and activities of daily living
and whether an increase in muscle strength will improve symptoms of claudication and lead to improvements in other
functional outcomes in patients with PAD. (J Vasc Surg 2013;57:963-73.)Intermittent claudication is a potentially disabling PAD. This potentially leads to loss of musculoskeletal and
symptom of peripheral arterial disease (PAD), which is
characterized by, but not limited to, calf pain that limits
walking. Intermittent claudication has been shown to
lead to skeletal muscle injury, characterized by a loss of
muscle ﬁbers and mild atrophy of the affected muscles.1
In addition, although research is limited, it has been shown
that oxidative metabolism is impaired,2,3 gait and mobility
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Evidence suggesting that a lower ankle-brachial index
(ABI), a measure of lower extremity ischemia, is related
to lower physical activity levels, slower walking speed,
shorter 6-minute walk distance (6MWD), and poorer
tandem stand performance in PAD5 has ignited interest
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Fig 1. Nagi disablement model tailored to the Regular Exercise for Peripheral Arterial Ischemia: a Randomized
Controlled Intervention Trial (REPAIR IT) pilot study hypotheses and outcomes. ABI, Ankle-brachial index; HGS,
habitual gait speed; MGS, maximal gait speed; RT, recovery time; SPPB, short physical performance battery. aThe
SPPB20 is a measure of lower extremity mobility14 and pools the results from the repeated chair stand, standing balance,
and habitual gait speed. A lower score equals poorer function.
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ness is causally related to the functional impairment and
reduced walking ability imposed by PAD.
Therefore, as represented in the Nagi disablement
model (Fig 1), this study aimed to ﬁrst test the hypothesis
that more severe PAD would be associated with both lower
muscle mass, strength, and endurance (proximate media-
tors), as well as more impaired mobility and functional
performance (distal outcomes). We hypothesized that
this relationship would be present despite the multiple
comorbidities present among a cohort with PAD that
may affect both the proximal mediators and distal out-
comes. Second, we hypothesized that those musculoskel-
etal impairments would also be directly associated with
reduced walking ability and more impaired functional
performance. Finally, we hypothesized that controlling
for musculoskeletal impairments would attenuate or elim-
inate the relationship between PAD severity and distal
outcomes of mobility and function, suggesting that
they mediate these relationships despite the presence of
mobility limitations from other comorbidities. The cross-
sectional characteristics of this cohort and testing of the
hypothesized relationships among these characteristics
are presented.
METHODS
This cross-sectional study was part of a randomized,
controlled pilot trial conducted by the University of Syd-
ney, titled REPAIR IT (Regular Exercise for Peripheral
Arterial Ischemia: a Randomized Controlled Intervention
Trial). Ethics approval was gained on October 18, 2009,
from St. Vincent’s Hospital (Reference #09/079) andthe University of Sydney (Reference #12334) Human
Research Ethics Committees. The trial was registered
with the Australia New Zealand Clinical Trials Registry
(ANZCTR #12609000457246). Participants (n ¼ 22)
were recruited into the study from July 2010 via direct
referral from clinics led by vascular surgeons. Written
informed consent was obtained before commencement of
baseline testing. Patients were included if they were older
than 50 years and suffered from intermittent claudication
from PAD conﬁrmed by a vascular surgeon. Exclusion
criteria included asymptomatic PAD, tissue necrosis or
gangrene, signiﬁcant cognitive impairment, inability to
comply with study requirements, and/or current participa-
tion in regular moderate- to high-intensity exercise.
Persons with speciﬁc contraindications to progressive resis-
tance training or who were awaiting surgical intervention
for PAD or other vascular disease also were excluded.
Primary outcomes. The ABI was measured twice after
10 minutes of supine rest using a LifeDop nondisplay
Doppler with an 8-MHz vascular probe (Summit
Doppler, Golden, Colo) per the American Heart Associa-
tion (AHA) guidelines.8 Each leg-speciﬁc ABI was then
calculated and classiﬁed according to the AHA interpreta-
tion of ABI.8 Participants whose ABI was >1.3 (n ¼ 1)
were excluded from analyses involving measurements
related to PAD. Each participant’s location of lesion,
identiﬁed via ultrasound within 6 months of commence-
ment of the trial, was classiﬁed as either 1 ¼ proximal
disease, where the lesion was located in the aortoiliac,
iliofemoral, or common femoral region; or 2 ¼ distal
disease, where the lesion was located in the superﬁcial
femoral, popliteal, and/or tibial arteries. Multilevel disease
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the below-knee level.
Participants performed a constant workload treadmill
walking test where the workload was set at the speed
and grade at which the individual participant reached
80% VO2 peak, measured during a maximum graded
treadmill stress test 1 week earlier. The exercise and ABI
testing protocols were conducted per AHA guidelines
for treadmill testing with ABI assessments.8 The time at
which claudication pain commenced was recorded and
converted to the initial claudication distance (ICD). If
a participant had rest pain, then the ICD was treated as
0 or 0.01 m to allow for statistical analysis. The time at
which the treadmill stopped was recorded and converted
to absolute claudication distance, and the reason for stop-
ping was also recorded. The time at which ankle pressures
returned to pre-exercise levels was recorded as the ABI
recovery time. In addition, the participant was asked to
notify the assessor as to when the claudication pain had
completely ceased. This was recorded as the claudication
recovery time.
The 6MW test was performed according to Guyatt
et al9 and AHA recommendations8 and was used to assess
ﬂat ground walking endurance. In addition, participants
were asked to notify the assessor as soon as claudication
commenced (6MW ICD). If participants needed to stop
during the test, the distance at which they stopped for
the ﬁrst time was recorded as the distance to ﬁrst stop. In
addition, the reason why they stopped was recorded. If
no stops were made during the test, the distance to ﬁrst
stop was recorded as the total walking distance covered
at completion of the 6 minutes (6MWD) to the nearest
0.1 m. At completion of the 6 minutes, the participants
were asked to sit down immediately and inform the assessor
when the pain had completely gone (claudication recovery
time). Each participant completed the 6MW twice at the
baseline assessment, 1 week apart, with the better of the
two trials used in statistical analysis. Previous randomized
controlled trials from our research laboratory have reported
the coefﬁcient of variance (CV) for this test as mean of
3.0% (range, 0.0%-13.0%).10
Secondary outcomes and clinical characteristics.
Demographic information was obtained using participant
self-report and checked by the assessor during each
assessment. Smoking and alcohol history, physical activity,
and comorbidities affecting walking and medical history
were initially obtained through interviews and conﬁrmed
through the physician screening. Comorbidity affecting
walking was a self-reported mobility limitation attributed
to a chronic condition. Each participant nominated the
predominant cause of mobility limitation other than clau-
dication, in his or her opinion. This was then coded as
a dichotomous variable (ie, present or not). Body mass
index was calculated and waist circumference was measured
according to the World Health Organization Expert
Committee protocols.11 Percent body fat, skeletal muscle
mass (SMM), and fat-free mass (FFM) were measured
according to Lange et al.10Peak dynamic muscle strength was assessed using digital
K400 Keiser pneumatic resistance machines (Keiser Sports
Health Ltd, Fresno, Calif). One-repetition maximum tests
were performed twice at baseline, 1 week apart, according
to the protocol of de Vos et al,12 with the higher results
used as the one-repetition maximum. Muscle strength was
tested bilaterally on knee extension, knee ﬂexion, chest
press, and seated row. Unilateral hip abduction and hip
extension strength were tested for each leg individually.
Bilateral hip extension was deﬁned as the summed unilateral
hip extension. Calf muscle strength was measured in kilo-
grams using the hack squat calf raise with range of motion
carefully monitored. Previous randomized controlled trials
from our research laboratory have reported a CV for these
exercises as mean of 13.1% (range, 9.8%-21.7%).10
Dynamic muscle endurance was tested on the same day
as muscle strength after resting and performed according to
Lange et al.10 Calf muscle endurance was measured by
asking the participant to complete as many full-range
standing calf raises as possible. Each calf raise was per-
formed on a step, with hands placed on a horizontal bar
for balance with range measured and monitored carefully.
Standing balance, chair stand, stair climb, and gait speeds
all were assessed as reported by Gates et al.13 Previous trials
in our laboratory have reported the CV for gait speed over
two trials as mean of 4.6 (range, 0.7%-12.5%).10 The short
physical performance battery (SPPB) was scored according
to McDermott et al.14,15
Statistical analysis. Outcomes were measured by
blinded assessors and analyzed using SPSS software
(PASW Statistics 18; IBM Corp, Armonk, NY). Data
were inspected for normality visually and statistically and
expressed as mean (standard deviation) or median (range),
as appropriate. A sample was considered skewed if the
standard error of the mean was # 1 or $ 1. Non-
normally distributed data were log transformed if possible
for use with parametric statistics. If normalization was not
possible, nonparametric statistics were substituted. Poten-
tial effects of medication usage and self-reported mobility
limitation on outcomes were analyzed using independent
sample t-tests. Relationships between potential predictors
of primary and secondary outcomes were determined by
simple, stepwise, and multiple regression models. Any
variables identiﬁed as signiﬁcant predictors of performance-
related outcomes were checked for colinearity and then
entered into a linear stepwise multiple regression model.
Covariates speciﬁed a priori include age, gender, and
severity of disease, and, if necessary, were adjusted for as
appropriate. Any score of 0 was treated as 0.01 for the
purpose of statistical analysis. Statistical signiﬁcance was
accepted at P # .05. A Bonferroni correction factor was
not used, as all hypotheses were speciﬁed a priori.16
RESULTS
Baseline characteristics. We identiﬁed and assessed
70 participants for eligibility from the vascular clinic located
at Concord Repatriation Hospital. The reasons for exclu-
sion of 48 potential participants is outlined in Fig 2.
Fig 2. REPAIR IT (Regular Exercise for Peripheral Arterial
Ischemia: a Randomized Controlled Intervention Trial) CONSORT
(Consolidated Standards of Reporting Trials) ﬂowchart. n ¼ sample
size.
Table I. Baseline characteristics
Characteristic Total cohort
Sample size, n 22
Age, years 73.6 (8.2)
Male, % 63.6
Body composition
Body mass index, kg/m2
Men 29.34 (4.47)
Women 23.89 (3.12)
Waist circumference, cm
Men 105.9 (89.8-120.7)
Women 80.8 (72.0-88.7)
Body fat, %
Men 31.79 (3.60)
Women 35.00 (5.03)
Alcohol frequency (standard drinksa per
week)
12 (12)
Current smoker, % 22.7
Ex-smoker, % 50.0
Smoking, pack-years 38 (30)
Overweight, % 50.0
Sedentary,b % 45.5
Risk factors for peripheral arterial disease, n 6 (1)
Framingham 10-y risk, % 16.8 (8.9)
CAD with MI, % 13.6
CAD without MI, % 40.9
Hypertension, % 81.8
Cerebrovascular disease, % 13.6
Hypercholesterolemia, % 95.5
Diabetes, % 18.2
Self-reported mobility limitation other than
peripheral arterial disease, %
68.2
Osteoarthritis of lower limb 36.4
Lower back pain 18.2
Stroke 4.5
Chronic obstructive pulmonary disease 4.5
Amputation 4.5
Statin, % 81.8
Nitrate, % 31.8
Warfarin, % 22.7
Antiplatelet agent, % 68.2
b-blocker, % 22.7
Cilostazol/pentoxifylline, % 0.0
Vitamin E, % 9.1
Fish oil, % 45.5
CAD, Coronary artery disease; MI, myocardial infarction.
Data are reported as mean (standard deviation) for normally distributed
continuous variables and as median (range) for non-normally distributed
variables.
aStandard drink was deﬁned as 1.5 standard drinks ¼ 1  375 mL of beer or
1  150 mL of wine.21
bSedentary living was deﬁned as a lifestyle that requires minimal physical
activity and that encourages inactivity through limited choices, disincen-
tives, and/or structural, physical, or ﬁnancial barriers.22
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summary of characteristics of participants is presented in
Table I . Mean (standard deviation) age of the 22 partici-
pants was 73.6 (8.2) years, and 14 participants (63.6%)
were men. On average, most men were overweight with an
average body mass index of 29.34 (4.47). Women on
average were within the healthy weight range, with body
mass index of 23.89 (3.12). Men, on average, had a larger
median waist circumference of 105.9 cm (range, 89.8-
120.7 cm) than the current recommendation of #94 cm
for men with cardiovascular disease.11 Women’s median
waist circumference of 80.8 cm (range, 72.0-88.7 cm) was
only slightly larger than the recommended #80 cm. Fifty-
ﬁve percent of the cohort drank alcohol on most days of
the week, with consumption averaging 12 (12) drinks per
week. In total, 73% of the cohort had a smoking history,
23% were current smokers, and 50% ex-smokers. Average
smoking consumption was a mean 38 (30) pack-years
(packs per day  years smoked). Almost half (45.5%) of
the cohort was sedentary, with an average of six of the nine
lifestyle and nonmodiﬁable risk factors for cardiovascular
disease (6.0 [1.1]).8,17 The Framingham 10-year risk score
was 16.8% (9%) on average.
Comorbidity associated with PAD was relatively
common, with 63.6% of the cohort having coronary artery
disease, including 13.6% who had experienced a previous
myocardial infarction. Only 13.6% of the cohort had cere-
brovascular disease. However, almost all participants
(95.5%) had hypercholesterolemia. In addition, most of
the cohort (81.8%) had hypertension and 18.2% had
diabetes, which is higher than the Australian national
age-speciﬁc prevalence of diabetes in 2004 to 2005 of
approximately 11.6%.18 Almost 70% of the cohort had
one or more chronic diseases, such as osteoarthritis, which
could have inﬂuenced habitual activity levels including
walking. Comorbidities affecting walking ability included
osteoarthritis of the lower limb (36.4%), lower back pain
(18.2%), stroke (4.5%), toe amputation (4.5%), and chronicobstructive pulmonary disease (4.5%). The majority of
participants (81.8%) were being treated with a 3-hydroxy-
3-methylglutaryl coenzyme A reductase inhibitor (statin)
and were taking antiplatelet medications (68.2%) or
warfarin (22.7%). Almost half of the cohort (45.5%) was
taking ﬁsh oil, with 9.1% taking vitamin E. No participants
were taking cilostazol or pentoxifylline.
The characteristics of participants according to the
severity of PAD are summarized in Table II. The duration
Table II. Baseline description of indexes of PAD severity
Characteristic Total cohort
Sample size, n 22
Disease duration (months) 18 (5-240)
American Heart Association ABI
classiﬁcation,a %
Noncompressible 4.5
Mild-to-moderate PAD 90.9
Severe PAD 4.5
Location of claudication, %
Buttock 4.5
Thigh 4.5
Calf 81.8
Multilevel 9.1
Location of PAD lesions, %
Proximal 40.9
Distal 59.1
Unilateral 40.9
Bilateral 59.1
Resting lowest ABI (either leg) 0.54 (0.13)
Reason for stopping during walking tests
Claudication 100%
One-min postexercise ABI (lowest leg) 0.25 (0.18)
Drop in ankle pressure postexercise, % 66.6 (28.1)
ABI recovery time, s 901.1 (536.6)
ABI, Ankle-brachial index; PAD, peripheral arterial disease.
Data are reported as mean (standard deviation) for normally distributed
continuous variables and as median (range) for non-normally distributed
variables.
aSubjects were then classiﬁed according to the American Heart Association’s
interpretation of ABI, where 0.00-0.40 ¼ severe PAD; 0.40-0.90 ¼ mild-
to-moderate PAD; 0.90-1.3 ¼ normal; and >1.30 ¼ noncompressible.8
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widely (median, 18 months; range, 5-240 months). Based
on the AHA ABI classiﬁcation scheme, the severity of
PADwas mild to moderate overall.8 Most participants expe-
rienced claudication symptoms in the calf only (81.8%). On
average, 40.9% of the cohort had proximal disease, 59.1%
had distal disease, and 59.1% had bilateral disease. Resting
ABI in the lowest leg was on average 0.54 (0.13), and partic-
ipants had a mean postexercise ABI of 0.25 (0.18), or a 66%
(28%) drop in ankle pressure in this same leg postexercise.
ABI returned to resting values at a mean of 901.1 (536)
seconds postexercise. There were no signiﬁcant relationships
between location of lesion or duration of symptoms and
walking ability and functional impairment.
The baseline descriptive statistics for mass, strength,
and endurance are outlined in Supplementary Table I
(online only). The SMM was higher on average in men
(28.42 [4.84] kg) than women (15.97 [2.58] kg; P <
.001). Men had both higher fat mass (25.78 [4.67] kg vs
20.71 [5.42] kg; P ¼ .03) and higher FFM (28.42
[4.84] vs 15.97 [2.58]; P < .001) than women. Partici-
pants who self-reported a mobility limitation other than
claudication had signiﬁcantly poorer calf muscle endurance
(P ¼ .04), and, although not yet signiﬁcant, they tended to
have poorer calf muscle strength (P ¼ .08). For all other
muscle mass, strength and endurance outcomes values
were generally similar between the two groups.The baseline descriptive statistics for walking ability
and functional performance in this cohort are outlined
in Supplementary Table II (online only). For all walking
and most performance-based outcomes, values were gener-
ally similar between those participants who self-reported
a mobility limitation other than claudication and those
who did not. Although not yet signiﬁcant, participants
who self-reported this limitation tended to have poorer
balance (P ¼ .06) and poorer performance in the SPPB
(P ¼ .09).
Inﬂuence of age and gender on musculoskeletal
impairment and functional performance. The SMM
(r ¼ e0.49; P ¼ .02), FFM (r ¼ e0.43; P ¼ .04), and
whole body muscle strength (r ¼ e0.66; P < .001) all
were lower with older age, and men were stronger than
women across all muscle groups (P ¼ .02). Therefore, in
order to assess the relationships between ABI and muscu-
loskeletal impairment and musculoskeletal impairment
and walking ability/functional performance (see Fig 1),
all analytical models were adjusted for age and gender.
Inﬂuence of smoking and alcohol on walking ability
in PAD. Greater smoking history (r ¼ 0.51; P ¼ .02; Fig
3, A) and greater current alcohol intake (r ¼ 0.57; P ¼
.007) were signiﬁcantly associated with longer claudication
recovery time (more severe disease). Because there was
a nearly signiﬁcant trend for men to have a higher alcohol
intake than women (P ¼ .052), gender was added to the
model of alcohol and claudication recovery time. This
relationship was attenuated but remained signiﬁcant after
controlling for gender in a multiple regression model (r ¼
0.50; P ¼ .03; Fig 3, B).
Testing the hypotheses relating disease, impair-
ment, and functional performance. We examined the
baseline data for evidence to support the Nagi model of
disability as presented in Fig 1. PAD severity was hypothe-
sized to be directly related to distal outcome, mobility, and
functional disability. One critical putative mechanism
underlying this relationship is the musculoskeletal impair-
ment caused by PAD, which in turn is hypothesized to
limit mobility and functional performance. Thus, if our
model is correct, the relationship between PAD severity
and distal outcomes should be attenuated or eliminated
once the proximate mediator, musculoskeletal impairment,
is controlled for. Evidence for each of these hypotheses in
this proposed pathway is examined in the following sections.
Relationship between PAD pathophysiology and
musculoskeletal impairment. The relationships between
ABI and body composition, muscle strength, and endurance
are outlined in Table III. Lower resting ABIwas signiﬁcantly
related to lower FFM(r¼ 0.34;P¼ .04),with a similar nearly
signiﬁcant trend for SMM(r¼ 0.25;P¼ .07). Therewas also
a direct association between ABI and total lower limb
strength (LLS; r ¼ 0.29; P ¼ .05), whole body muscle
strength (r ¼ 0.32; P ¼ .05), and bilateral hip extensor
strength (HES; r ¼ 0.54; P ¼ .007). The relationship
between ABI and HES became even more signiﬁcant after
appropriately controlling for both age and gender in
a multiple regression model (r ¼ 0.54; P ¼ .004; Fig 4).
Fig 3. Relationship between smoking and alcohol consumption
and indexes of peripheral arterial disease (PAD) severity. Simple
linear regression between claudication recovery time (CRT) as an
index of PAD severity and lifestyle factors. A, Greater smoking
history was signiﬁcantly associated with longer recovery time
(more severe disease; r ¼ 0.51; P ¼ .02). B, Greater alcohol intake
was also signiﬁcantly associated with longer recovery time (r ¼
0.57; P ¼ .007). Because there was a nearly signiﬁcant trend for
men to have a higher alcohol intake than women (P ¼ .052),
gender was added to the model. This relationship attenuated but
remained signiﬁcant after controlling for gender in a multiple
regression model (r ¼ 0.50; P ¼ .03). The r and P values were
calculated by linear regression analysis. CTrd, Constant treadmill
protocol.
Table III. Baseline resting ABI as a predictor of body
composition, muscle strength, and endurance
Characteristic Resting ABI
Skeletal muscle mass,a kg r ¼ 0.25; P ¼ .07b,c
Fat mass,a kg r ¼ e0.48; P ¼ .04b,c
Fat-free mass,a kg r ¼ 0.34; P ¼ .04b,c
Calf strength, kg r ¼ 0.10; P ¼ .62b,c
Calf endurance, repetitions r ¼ 0.42; P ¼ .12
Bilateral knee extensor strength, N r ¼ 0.25; P ¼ .12b,c
Bilateral hip extensor strength, N-m r ¼ 0.54; P ¼ .004b,c
Total lower limb strength, N r ¼ 0.29; P ¼ .05b,c
Whole body strength, N r ¼ 0.32; P ¼ .05b,c
ABI, Ankle-brachial index; N, newtons; N-m, newton-meters.
The r value represents the correlation coefﬁcient unless otherwise stated.
aSkeletal muscle mass (SMM), fat-free mass (FFM), and fat mass (FM) were
calculated using bioelectrical impedance analysis and the following
formulas: SMM ¼ 0.401 (height in square centimeters/resistance in
ohms) þ 3.825 (1 for male or 0 for female) þ age in years (e0.071) þ
5.10223 FFM ¼ e4.03 þ 0.734 (height in square centimeters/resistance in
ohms) þ 0.116 (body weight in kilograms) þ 0.096 (reactance in ohms) þ
0.984 (1 for male or 0 for female)24 FM ¼ Body weight e FFM.24
bControlled for gender.
cControlled for age.
Fig 4. Relationship between ankle-brachial index (ABI) and
bilateral hip extensor strength. Simple linear regression between
ABI and bilateral hip extensor strength. Low ABI was signiﬁcantly
associated with reduced bilateral hip extensor strength (r ¼ 0.54;
P ¼ .007). Because bilateral hip extensor strength reduced with
age (P ¼ .005) and women had weaker hip extensors than men
(P ¼ .04), age and gender were added to the model. This rela-
tionship remained after controlling for both age and gender in
a multiple regression model (r ¼ 0.54; P ¼ .004). The r and P
values were calculated by linear regression analysis.
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impairment, SMM and muscle function were themselves
highly correlated. Speciﬁcally, there were signiﬁcant direct
relationships between SMM and FFM and bilateral HES
(r ¼ 0.69; P ¼ .007; r ¼ 0.69; P ¼ .007); total LLS
(r ¼ 0.79; P ¼ .02; r ¼ 0.76; P ¼ .02); and whole
body strength (WBS; r ¼ 0.85; P ¼ .002; r ¼ 0.84;
P ¼ .002), respectively. Therefore, we constructed a step-
wise multiple regression model to determine if thesefactors were independent of each other with respect to
their relationship to ABI. When both HES and FFM
were entered into a stepwise regression model with ABI
as the dependent variable, ABI was no longer signiﬁcantly
related to FFM (r ¼ 0.22; P ¼ .38), suggesting that the
apparent relationship between ABI and FFM was largely
Table IV. Baseline muscle mass and strength as predictors of walking ability and functional performance
Characteristic Skeletal muscle mass,a kg Calf strength, kg Bilateral hip extensor strength, N-m
6MW ICD, m r ¼ 0.58; P ¼ .18d,e r ¼ 0.53; P ¼ .10d,e r ¼ 0.47; P ¼ .08d,e
6MWD ﬁrst stop, m r ¼ 0.51; P ¼ .04d,e r ¼ 0.46; P ¼ .75d,e r ¼ 0.74; P ¼ .005d,e
6MWD, m r ¼ 0.31; P ¼ .34d,e r ¼ 0.49; P ¼ .28d,e r ¼ 0.75; P < .001d,e
HGS, m/s r ¼ 0.18; P ¼ .32d,e r ¼ 0.46; P ¼ .08d,e r ¼ 0.58; P ¼ .007d,e
MGS, m/s r ¼ 0.23; P ¼ .55d,e r ¼ 0.63; P ¼ .003d,e r ¼ 0.58; P ¼ .01d,e
Stair power,b W r ¼ 0.60; P ¼ .04d,e r ¼ 0.76; P ¼ .006d,e r ¼ 0.78; P ¼ .001d,e
Five-chair stand time, seconds r ¼ e0.08; P ¼ .28d,e r ¼ e0.41; P ¼ .12d,e r ¼ e0.43; P ¼ .03d,e
Static balance, seconds r ¼ e0.18; P ¼ .75d,e r ¼ 0.13; P ¼ .58d,e r ¼ 0.44; P ¼ .02d,e
SPPB scorec r ¼ e0.08; P ¼ .54d,e r ¼ 0.36; P ¼ .16d,e r ¼ 0.59; P ¼ .003d,e
6MW, 6-Minute walk; 6MWD, 6-minute walk distance; ICD, initial claudication distance; HGS, habitual gait speed;MGS, maximal gait speed; m/s, meters per
second; N-m, newton-meters; SPPB, short physical performance battery; W, watts.
The r value represents the correlation coefﬁcient unless otherwise stated.
aSkeletal muscle mass (SMM) was calculated using bioelectrical impedance analysis and the following formula: SMM ¼ 0.401 (height in square centimeters/
resistance in ohms) þ 3.825 (sex: male ¼ 1; female ¼ 0) þ age in years (e0.071) þ 5.102.23
bStair climb power was calculated using the following formula25,26: Power (in watts) ¼ [Body weight (in newtons) Height of stairs (in meters)]/Ascent time
(in seconds).
cThe SPPB20 is a measure of lower extremity mobility14 and pools the results from the repeated chair stand, standing balance, and habitual gait speed. A lower
score equals poorer function.
dControlled for gender.
eControlled for age.
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The remaining strength variables were not used in step-
wise regression models with FFM and ABI due to colin-
earity (r > 0.7) with FFM (see above). Thus, ABI was
associated with lower strength, independent of differences
in muscle mass.
ABI as a predictor of walking ability and functional
performance at baseline in PAD. Lower ABI was associ-
ated with a shorter 6MW ICD (r ¼ 0.48; P ¼ .03) and
distance to ﬁrst stop (r ¼ 0.38; P ¼ .05), and there was
a nearly signiﬁcant association between a lower ABI and
a shorter 6MWD (r ¼ 0.36; P ¼ .06). Lower ABI was also
associated with worse balance in single leg stance (r ¼
0.44;P¼ .03) and tended to be associatedwith lower overall
functional performance via SPPB score (r ¼ 0.36; P ¼ .06).
Muscle mass, strength, and endurance as predictors
of walking ability and functional performance at base-
line in PAD. The relationships between muscle mass,
strength, and endurance as predictors of walking ability
and functional performance in patients with PAD are out-
lined in Table IV. Participants with lower SMM stopped
signiﬁcantly earlier during the 6MW (r ¼ 0.51; P ¼ .04).
Participants with lower bilateral HES (r ¼ 0.74, P ¼ .001;
Fig 5, A), lower total lower limb muscle strength (r ¼ 0.63;
P ¼ .008), and lower WBS (r ¼ 0.60; P ¼ .01) also stopped
signiﬁcantly earlier during the 6MW. Furthermore,
participants with lower bilateral HES (r ¼ 0.75, P < .001;
Fig 5, B), lower total lower limb muscle strength (r ¼ 0.67;
P ¼ .001), and lower WBS (r ¼ 0.65; P ¼ .001) walked
signiﬁcantly less in 6 minutes, respectively. In addition,
participants with lower WBS had an earlier onset of
claudication during the 6MW (r ¼ 0.45; P ¼ .01).
Participants with weaker calf muscles had a signiﬁcantly
longer claudication recovery time on a constant treadmill
protocol (r ¼ e0.61; P ¼ .02). Thus, the relationships
between musculoskeletal impairment and claudicationoutcomes were in general stronger and broader than those
relating ABI to claudication directly (see above).
There was a signiﬁcant direct relationship between
SMM and stair climb power (r ¼ 0.60; P ¼ .04). Partici-
pants with lower calf muscle strength had a slower maximal
gait speed (r ¼ 0.63; P ¼ .003) and reduced stair climb
power (r ¼ 0.76; P ¼ .006). Participants with reduced
bilateral HES, reduced total LLS, and reduced WBS had
a slower habitual gait speed (HES, r ¼ 0.58; P ¼ .007;
LLS, r ¼ 0.47; P ¼ .01; WBS, r ¼ 0.49; P ¼ .04, respec-
tively), slower maximal gait speed (HES, r ¼ 0.58; P ¼ .01;
LLS, r ¼ 0.49; P ¼ .02; WBS, r ¼ 0.51, P ¼ .01, respec-
tively), reduced stair climb power (HES, r ¼ 0.78;
P ¼ .001; LLS, r ¼ 0.75; P ¼ .003; WBS, r ¼ 0.78;
P ¼ .001, respectively), reduced total static balance
(HES, r ¼ 0.44; P ¼ .02; LLS, r ¼ 0.42; P ¼ .007;
WBS, r ¼ 0.42; P ¼ .007, respectively), and reduced
SPPB score (worse function; HES, r ¼ 0.75; P ¼ .003;
Fig 5, C; LLS, r ¼ 0.41; P ¼ .01; WBS, r ¼ 0.40;
P ¼ .02, respectively). The relationship between SMM
and stair climb power was attenuated and no longer signif-
icant (r ¼ 0.19; P ¼ .42) when HES was added to the
model (Table V, model 1). Thus, a variety of different
measures of whole body and LLS were strongly related
to every functional performance variable we measured, as
hypothesized. These relationships were far broader and
more signiﬁcant than the few trends we observed for ABI
itself to predict functional performance.
Relationship between ABI and walking ability/
functional performance is attenuated once musculo-
skeletal impairment is added to the model. In support of
our ﬁrst hypothesis, as shown above, more severe PAD
(lower ABI) was associated with lower FFM, lower muscle
strength, and poorer walking ability (earlier claudication)
and tended to be associated with poorer performance
in functional performance outcomes (gait, chair stand,
Fig 5. Relationship between bilateral hip extensor strength and
walking ability and functional performance in subjects with
peripheral arterial disease. A and B, Simple linear regression
between bilateral hip extensor strength (HES) and the distance to
ﬁrst stop and total walking distance for the 6-minute walk (6MW).
Reduced HES was signiﬁcantly associated with a shorter distance
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second hypothesis, greater musculoskeletal impairment, as
measured by lower SMM and muscle strength, was associ-
ated with an even greater degree than ABI itself with
poorer walking ability and signiﬁcantly worse performance
in functional outcomes. To conﬁrm whether the relation-
ships between ABI and walking ability or function could
be explained by variation in muscle mass and/or muscle
strength (hypothesis 3), we controlled for muscle mass
and strength in separate stepwise multiple regression
models of these outcomes.
Therefore, the independent variables ABI and bilateral
HES (both predictive of 6MWD to ﬁrst stop) were entered
into a stepwise regression model (Table V, model 2). Only
bilateral HES remained a signiﬁcant predictor (r ¼ 0.74; P
< .001) in the model for 6MWD to ﬁrst stop. Similarly, the
independent variables ABI and bilateral HES (both predic-
tive of 6MWD) were entered into a separate stepwise
regression model (Table V, model 3). Only bilateral HES
remained a signiﬁcant predictor (r ¼ 0.74; P < .001) in
the model for 6MWD. Finally, the independent variables
ABI and bilateral HES (both predictive of single leg
balance) were entered into a separate stepwise regression
model (Table V, model 4). Only bilateral hip extensor
strength remained a signiﬁcant predictor in the model
(r ¼ 0.48; P ¼ .03) for single leg balance. Because the pres-
ence of a self-reported mobility limitation tended to affect
single leg balance, we added this to the stepwise regression
model. The relationship between bilateral HES and single
leg balance remained unchanged once the presence of
a comorbidity affecting performance was appropriately
controlled for. Therefore, in all three stepwise models,
the ABI relationship was attenuated and no longer signiﬁ-
cant once muscle strength was included in the model.
Thus, muscle strength appears to mediate the relationship
between ABI and distal walking and functional outcomes
in this cohort.to ﬁrst stop during ﬂat ground walking (A; r ¼ 0.74; P < .001)
and reduced total 6-minute walk distance (B; 6MWD; r ¼ 0.75; P
< .001). Because the distance to ﬁrst stop reduced with age (P ¼
.02) and men were signiﬁcantly stronger than women (P ¼ .004),
age and gender were added to the distance to ﬁrst stop model and
gender to the 6MWD models. These relationship remained after
controlling for age and gender in these multiple regression models
(r ¼ 0.74; P ¼ .001; r ¼ 0.75; P < .001 respectively). C, Simple
linear regression between HES and short physical performance
battery (SPPB) score. (The SPPB20 is a measure of lower extremity
mobility14 and pools the results from the repeated chair stand,
standing balance, and habitual gait speed. A lower score equals
poorer function.) Reduced HES was signiﬁcantly associated with
reduced SPPB score (worse function; r ¼ 0.59; P ¼ .002). Because
HES reduced with age (P ¼ .004) and women had weaker hip
extensors than men (P ¼ .04), age and gender were added to the
model. This relationship became stronger after controlling for
both age and gender in a multiple regression model (r ¼ 0.75; P ¼
.003). The r and P values were calculated by linear regression
analysis.
Table V. Stepwise regression models relating a reduction in ABI to muscle weakness and reduced walking ability
Model Variables entereda Variables removed Variables remaining r value P value
1 Stair climb power
SMM
BL HES
SMM Stair climb power
BL HES
0.78 <.001
2 6MW ﬁrst stop
ABI
BL HES
ABI 6MW ﬁrst stop
BL HES
0.74 <.001
3 6MWD
ABI
BL HES
ABI 6MWD
BL HES
0.74 <.001
4 Single leg balance
ABI
BL HES
Comorbidity
ABI
Comorbidity
Single leg balance
BL HES
0.48 .03
6MW, 6-Minute walk; 6MWD, 6-minute walk distance; ABI, ankle-brachial index; BL HES, bilateral hip extensor strength; SMM, skeletal muscle mass.
The r value represents the correlation coefﬁcient unless otherwise stated.
aAge and gender were added to all ﬁve stepwise regression models.
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ships between PAD severity and walking and functional
outcomes were attenuated and no longer signiﬁcant once
muscle strength was taken into account. In addition, the
relationships between SMM and distal outcomes all were
eliminated when adjusted for strength, suggesting that it
was the musculoskeletal dysfunction related to muscle
atrophy itself rather than loss of muscle mass per se that
was directly linked to reduced mobility and function in
this cohort.
DISCUSSION
Our results conﬁrm that greater severity of PAD
(deﬁned by a lower resting ABI) was associated with lower
FFM and a similar nearly signiﬁcant trend for SMM, lower
muscle strength, as well as poorer walking ability and
performance-based tests of function (gait, stair climbing,
chair rising, and balance). Because lower muscle mass and
muscle strength were themselves signiﬁcantly related to
poorer walking ability and performance-based tests of func-
tion, we further hypothesized that these musculoskeletal
impairments might underlie the apparent effect of PAD
on walking/ability and functional performance. In support
of this potential mechanistic pathway, the relationships
between PAD and walking ability/functional performance
were no longer signiﬁcant once we controlled for muscle
strength. Furthermore, muscle mass differences did not
explain additional variance in walking or functional
outcomes beyond that attributable to muscle strength
itself. Thus, our overall results suggest that sarcopenia
and its related muscle dysfunction underlie a signiﬁcant
portion of the functional deﬁcits observed in PAD. These
relationships are consistent with the Nagi model of
disability19 (see Fig 1), wherein the active pathology,
PAD (low ABI), leads to impairment of muscle mass and
thereby strength, leading to limitations in walking ability
and performance-based tests of function, including gait
speed, chair stand, balance, stair climb, and summarySPPB score. Nagi recognized that the consequence of
disease for an individual should be described at the level
of both the person and society, and highlighted that such
a limitation in performance of functional tasks is highly
predictive of future disability, or the inability of a person
to perform necessary social roles19 and subsequently of
more basic activities of daily living. Future trials should
investigate whether preventing or attenuating this sarcope-
nia and associated muscle dysfunction would ultimately
improve mobility and functional dependency in this cohort.
The novel design of this study, compared with other
trials assessing muscle strength, are the speciﬁc procedures
involved in muscle strength testing, including the number
of muscle groups assessed as well as the precise measure-
ment of maximum dynamic muscle strength using well-
established one-repetition maximum protocols.12 Dynamic
muscle strength is far more applicable to walking and activ-
ities of daily living and has never before been used in
a cohort with PAD. This randomized controlled trial
assessed maximum dynamic muscle strength across seven
separate muscle groups, including the calf muscle, quadri-
ceps, hamstrings, hip abductors, hip extensors, pectorals,
and upper back muscle groups. This enabled us to analyze
relationships for individual muscle groups as well as
combined groups to help identify the exact muscle groups
with impaired muscle strength and endurance in this
cohort and furthermore, which muscle groups were specif-
ically related to walking impairment. This has never before
been done in cohorts with PAD. Our results conﬁrm that
the strongest predictor of walking ability and the ability
to complete performance-based tests of function was bilat-
eral HES, when compared with other muscle groups. In
addition, stronger calf muscles were associated with
a quicker claudication recovery time. Because the hip
extensors were such a strong mediator of walking and func-
tional outcomes, future trials should aim to strengthen
these muscles and investigate the effect this has on
a person’s walking ability and ability to perform activities
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gait analysis in future trials would better deﬁne how
strengthening the hip extensors and calf muscles may
improve walking/functional ability in this cohort.
The relationships we presented all support the hypoth-
esis that an anabolic exercise intervention aimed at
improving WBS and overall muscle function could improve
the functional limitations caused by the physiologic impair-
ments imposed by PAD. Future trials should aim to
compare the effects of strengthening various muscle
groups, with particular focus on those we have identiﬁed
as most strongly related to PAD and walking outcomes
in claudicants: hip extensors and plantar ﬂexors.
CONCLUSIONS
A lower ABI is related to lower FFM and poorer HES,
WBS, and walking ability and functional performance. In
addition, poor bilateral HES is signiﬁcantly related to
a shorter distance to ﬁrst stop, reduced total walking
distance, and poorer scores for performance-based tests
of function. Our results suggest the existence of a causal
pathway from local disease pathophysiology (reduction in
ABI) to impairment of the musculoskeletal system (atrophy
and weakness) to whole body disability represented by
claudication outcomes and performance-based tests of
functional mobility in an older cohort with symptomatic
PAD. Longitudinal outcomes from the REPAIR IT study
and future trials are required to investigate the effects of
an anabolic intervention targeting the muscles involved in
gait to test the hypothesis that an increase in lower limb
muscle strength and mass will improve symptoms of claudi-
cation and lead to improvements in other functional
outcomes in patients with PAD.
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Supplementary Table I (online only). Baseline
descriptive statistics for body mass, strength, and
endurance and the effect of self-reported mobility
limitation
Characteristic Total pilot cohort P valuea
Sample size, n 22
Skeletal muscle mass,b kg
Men 28.42 (4.84) .31
Women 15.97 (2.58) .76
Fat mass,b kg
Men 25.78 (4.67) .96
Women 20.71 (5.42) .90
Fat free mass,b kg
Men 28.42 (4.84) .44
Women 15.97 (2.58) .99
Calf strength, kg 10 (10) .08
Calf endurance, repetitions 17 (7-50) .04
Knee ﬂexor strength, N 393 (153) .87
Knee ﬂexor endurance, N 1598 (153-6435) .80
Knee extensor strength, N 99 (57) .24
Knee extensor endurance, N 552 (465) .85
Bilateral hip extensor
strength, N-m
231 (130) .19
Bilateral hip extensor
endurance, N
1276 (928) .62
Total lower limb strength, N 873 (401) .37
Total lower limb endurance, N 3703 (2534) .96
Chest press strength, N 121 (58) .72
Seated row strength, N 161 (64) .80
Whole body strength, N 987 (415) .58
N, Newtons; N-m, newton-meters.
Data are reported as mean (standard deviation) for normally distributed
continuous variables and as median (range) for non-normally distributed
variables.
aBetween-group value for participants who self-reported a mobility limita-
tion and those who did not.
bSkeletal muscle mass (SMM), fat-free mass (FFM), and fat mass (FM) were
calculated using bioelectrical impedance analysis and the following
formulas: SMM ¼ 0.401 (height in square centimeters/resistance in
ohms) þ 3.825 (sex: male ¼ 1; female ¼ 0) þ age in years (e0.071) þ
5.10223 FFM ¼ e4.03 þ 0.734 (height in square centimeters/resistance in
ohms) þ 0.116 (body weight in kilograms) þ 0.096 (reactance in ohms) þ
0.984 (sex: male ¼ 1; female ¼ 0)24 FM ¼ Body weight e FFM.24
Supplementary Table II (online only). Baseline
descriptive statistics for walking ability and functional
performance and the effect of self-reported mobility
limitation
Characteristic Total pilot cohort P valuea
Sample size, n 22
CTrd initial claudication
distance, m
119.9 (63.0) .87
CTrd absolute claudication
distance, m
447.9 (305.8) .79
Claudication recovery
time, seconds
178.8 (107.5) .64
GTrd initial claudication
distance, m
165.7 (91.8) .86
GTrd absolute claudication
distance, m
296.2 (129.6) .74
6MW distance to ﬁrst stop, m 375.9 (164.9) .82
6MWD, m 415.7 (104.9) .92
Habitual gait speed, m/s 1.13 (0.29) .79
Maximal gait speed, m/s 1.54 (0.42) .52
Stair climb power,b W 236.1 (108.0) .25
Five-chair stand time, seconds 11.7 (8.0-108.0) .36
Semitandem balance, seconds 15.0 (0.0) .99
Tandem stand balance, seconds 15.0 (0.7-15.0) .19
Single leg balance eyes open,
seconds
15.0 (0.0-15.0) .21
Single leg balance eyes closed,
seconds
2.4 (1.3) .06
Total static balance, seconds 76.60 (41.9-79.3) .09
SPPB scorec 11 (4-12) .09
6MWD, 6-Minute walk distance; CTrd, constant treadmill protocol; GTrd,
graded treadmill protocol; m/s, meters per second; SPPB, short physical
performance battery; W, watts.
Data are reported as mean (standard deviation) for normally distributed
continuous variables and median (range) for non-normally distributed
variables.
aBetween-group value for participants who self-reported a mobility limita-
tion and those who did not.
bStair climb power was calculated using the following formula25,26: Power
(in watts) ¼ [Body weight (in newtons)  Height of stairs (in meters)]/
Ascent time (in seconds).
cThe SPPB20 is a measure of lower-extremity mobility14 and pools the
results from the repeated chair stand, standing balance, and habitual gait
speed. A lower score equals poorer function.
JOURNAL OF VASCULAR SURGERY
973.e1 Parmenter et al April 2013
